SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

9 Apr 2015 07:00

RNS Number : 6595J
Victrex PLC
09 April 2015
Β 

ο»Ώ

Β 

Β 

Β 

Β 

Β 

9 April 2015

Victrex plc

Half year and pre-close trading update

'A good first half; well positioned for full year progress'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its half year and pre-close trading update for the six months ended 31 March 2015.

Overall, Victrex delivered a good first half performance. Group revenue of Β£130.3m was 9% ahead of the prior year (H1 2014: Β£119.9m), with Group sales volume of 2,028 tonnes 28% ahead of the prior year (H1 2014: 1,584 tonnes). The first half performance reflects a continuing positive contribution from Consumer Electronics and slightly lower sales in our Invibio medical business. Group gross margins saw improvement compared to the first half of 2014, reflecting better manufacturing efficiencies.

In Victrex Polymer Solutions (VPS), lower sales into oil and gas were offset by growth in our other markets. Commissioning of the first production stream on our third PEEK manufacturing plant is now complete and successfully started up on schedule. In Invibio, performance reflected the impact from industry consolidation in the US during Q1, as previously communicated, although we saw an improvement in Q2. Invibio revenue of Β£25.9m was 4% down on the prior year (H1 2014: Β£26.9m) and flat in constant currency, although our focus remains on continued improvement as we enter the second half.

The adverse currency impact seen by the Group during the first half will also continue into the second half. However, as previously communicated, we continue to expect that we will fully overcome the currency impact for the full year.

David Hummel, Chief Executive of Victrex, said: "Victrex delivered a good first half performance overall. Although we are mindful of the tougher comparatives for the second half and the continued caution in the oil and gas market, we remain well positioned for progress over the full year."

Victrex will report its interim results on Tuesday 19 May 2015.

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

Β 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

Β 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver new and leading edge solutions to our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTUGUCPCUPAGAR
Date   Source Headline
10th May 20231:34 pmRNSDirector/PDMR Shareholding
9th May 20237:00 amRNSVictrex plc - Interim Results 2023
28th Apr 20239:33 amRNSTotal Voting Rights
18th Apr 20232:00 pmRNSHolding(s) in Company
18th Apr 202310:50 amRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSDirectorate Change
31st Mar 202310:52 amRNSTotal Voting Rights
20th Mar 20233:07 pmRNSHolding(s) in Company
20th Mar 202310:15 amRNSDirector/PDMR Shareholding
13th Mar 202310:14 amRNSAdditional Listing
28th Feb 20239:35 amRNSTotal Voting Rights
17th Feb 202310:06 amRNSDirector/PDMR Shareholding
14th Feb 202312:20 pmRNSDirector/PDMR Shareholding
10th Feb 20232:12 pmRNSDirector/PDMR Shareholding
10th Feb 202312:29 pmRNSResult of AGM
10th Feb 20237:00 amRNSAGM & Q1 Interim Management Statement
31st Jan 202310:43 amRNSTotal Voting Rights
17th Jan 20232:12 pmRNSDirector/PDMR Shareholding
12th Jan 20232:28 pmRNSCorrection - AGM Resolution Proposal
6th Jan 20232:58 pmRNSAnnual Report and Accounts
30th Dec 20229:00 amRNSTotal Voting Rights
22nd Dec 202211:30 amRNSDirector/PDMR Shareholding
19th Dec 202212:04 pmRNSDirector/PDMR Shareholding
19th Dec 202210:56 amRNSDirector/PDMR Shareholding
13th Dec 202211:16 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSVictrex plc – Preliminary Results 2022
1st Dec 202211:49 amRNSBlock listing Interim Review
30th Nov 20229:27 amRNSTotal Voting Rights
29th Nov 20224:05 pmRNSHolding(s) in Company
17th Nov 20222:50 pmRNSDirector/PDMR Shareholding
17th Nov 20221:35 pmRNSAdditional Listing
31st Oct 202212:55 pmRNSTotal Voting Rights
18th Oct 202212:26 pmRNSDirector/PDMR Shareholding
30th Sep 202211:03 amRNSTotal Voting Rights
28th Sep 20229:44 amRNSHolding(s) in Company
20th Sep 20224:05 pmRNSDirector/PDMR Shareholding
31st Aug 20229:00 amRNSTotal Voting Rights
17th Aug 20222:31 pmRNSDirector/PDMR Shareholding
29th Jul 202210:01 amRNSTotal Voting Rights
19th Jul 20222:41 pmRNSDirector/PDMR Shareholding
7th Jul 20227:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202210:28 amRNSTotal Voting Rights
21st Jun 202212:41 pmRNSDirector/PDMR Shareholding
7th Jun 202211:45 amRNSBlock listing Interim Review
31st May 20229:59 amRNSTotal Voting Rights
27th May 20229:40 amRNSHolding(s) in Company
17th May 20223:58 pmRNSHolding(s) in Company
17th May 202212:19 pmRNSDirector/PDMR Shareholding
13th May 202211:02 amRNSDirector/PDMR Shareholding
9th May 20227:00 amRNSVictrex plc – Interim Results 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.